Ras association domain family member 6Genealiases: []
Q-omics provides the consensus-scored RASSF6 profile across patient tissues and cancer cell-line models. RASSF6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RASSF6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, RASSF6 RNA expression shows 16,573 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where RASSF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF6 survival associations across molecular data types. RASSF6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF6 RNA expression–survival associations across cancer types. High RASSF6 expression shows unfavorable associations in THCA, but favorable associations in KIRC, SKCM, MESO, BRCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RASSF6 RNA expression.
This table summarizes RASSF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RASSF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF6 shows lower tumor expression in THCA, COAD and BRCA and higher tumor expression in KIRC, KIRP and UCEC. The THCA box plot shows higher RASSF6 RNA expression in normal versus tumor tissue (log2 FC = −2.566, t-test p < 0.001).
This table shows molecular features associated with RASSF6 in patient tissues and cancer cell lines. In patient samples, RASSF6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
